- Alcami Corporation has acquired a 37,000-square-foot facility in Durham, North Carolina, for $6.7 million to expand analytical and development capabilities.
- The site will support complex therapeutics and complements existing lab, sterile fill-finish, and cGMP storage operations in the Research Triangle region.
Alcami Corporation has acquired a 37,000-square-foot, two-story facility at 4620 Creekstone Drive in Durham, North Carolina, as part of a $6.7 million investment to expand advanced laboratory services. The site is located in Research Triangle Park and will serve as a hub for the company’s growing analytical and development operations.
The acquisition supports plans announced in October for a major laboratory expansion at the Durham site, scheduled for completion later this year. Alcami said the expanded capabilities will support a broad range of complex therapeutics, including biologics, peptides, proteins, oligonucleotides, and cell and gene therapy drug substances, strengthening its CDMO and contract manufacturing offerings.
“This acquisition marks another milestone in our strategy to deliver innovative, scalable solutions for our clients in the growing area of biologics. By expanding our analytical lab capabilities in RTP, we’re able to support innovators in bringing life-changing therapies to patients faster and more reliably.”
Katie Schlipp, President, Lab Operations at Alcami
The Creekstone Drive facility complements Alcami’s existing laboratory operations, sterile fill-finish manufacturing, and cGMP storage in the RTP area, as well as its wider U.S. network. The company recently qualified a third sterile fill-finish line at its RTP campus, bringing its total to five GMP-compliant lines for clinical and commercial manufacturing, reinforcing its strategy to streamline development and support reliable supply.
